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Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic ﬁbrosis patients is not well understood.
Methods: Using ﬁve antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early
Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa
isolation post eradication.
Results: Baseline positive P. aeruginosa serology was not signiﬁcantly associated with failure of initial P. aeruginosa eradication measured at
week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was signiﬁcantly associated with
increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively).
There was no association between baseline seropositivity and time to pulmonary exacerbation.
Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa
in CF patients.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas; Serology; Treatment; Infection; EPIC1. Introduction
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,lishedseveral antibiotic regimens have demonstrated that eradication
of the pathogen from the patients' airways is possible when
therapy is initiated in the acute phase of infection early after
isolation. This strategy has been associated with considerably
delaying the onset of chronic pulmonary P. aeruginosa infection
in CF patients, decreasing the progression of lung disease, and
reducing the cost of antibiotic intervention [1,2]. A prerequisite
for applying this therapeutic strategy is close monitoring of
P. aeruginosa isolation in CF subjects based on the assumption
that the therapeutic window is small and the switch of non-mucoid
P. aeruginosa to biofilm formation would render eradication of
the pathogen difficult or impossible [3]. Detection is generallyby Elsevier B.V. All rights reserved.
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sputum or bronchoalveolar lavage (BAL) specimens [4,5]. In the
US, the standard of care for detection of initial P. aeruginosa
infection in pre-expectorating patients is to collect routine OP
cultures at least every 3 months [6]; Furthermore, while OP
cultures are easy to perform on a frequent basis, they appear to only
moderately reflect lower airway infection [7]. Serological tests
have been used to diagnose P. aeruginosa, particularly in patients
who do not produce sputum (reviewed in [3,8]). However, this
method has not been unequivocally accepted due in part to
differences in patient population, study design, and cut-off
antibody titers among various studies [9–12].
P. aeruginosa serology has been demonstrated to be an
adjunct method for assessment of early eradication therapy
[2,8,13], because bacterial culturing, particularly from nasopha-
ryngeal aspirates and OP cough swab specimens, is subject to
sampling error, and imperfect diagnostic accuracy [7]. Highly
sensitive ELISAs for detection of serum antibodies against
P. aeruginosa antigens in immunocompetent CF patients may
complement less than perfect surveillance methods such as OP
swabs. Several assay systems have been developed, for different
P. aeruginosa antigens such as P. aeruginosawhole cell proteins
and exotoxin A [14,15], exotoxin A, elastase and alkaline
protease [2,8,13,16], and components of the type III secretion
system [17,18].
Elevated antibodies among young subjects at the time of
initial P. aeruginosa positive OP culture may be a useful tool
for CF clinicians and researchers monitoring patients at risk for
subsequent infection. Here we demonstrate the relationship
between culture and serologic data available in subjects with
newly acquired P. aeruginosa infection participating in the
multi-center Early Pseudomonas Infection in Children (EPIC)
trial [19] and determine if baseline P. aeruginosa serology
would predict treatment failure, time to pulmonary exacerba-
tion and risk for re-isolation of P. aeruginosa post eradication.2. Methods
2.1. Subjects and serologic analysis
Subjects with CF, recruited for the EPIC Clinical trial, were
1–12 years of age and had P. aeruginosa isolated within six
months prior to study entry [19]. The study consisted of an
initial 10 week treatment period (in an attempt to eradicate
P. aeruginosa) plus 60 weeks of follow up. Serum specimens,
collected during the EPIC trial at weeks 0, 22, 46 and 70, were
used in the present study to assess antibody titers against
P. aeruginosa. Data from up to eight respiratory cultures were
available from weeks 0, 3, 10, 22, 34, 46, 58 and 70, to
compare serological data to standard of care OP culture results.
For serology, the E-15 ELISA kit (Mediagnost, Reutlingen,
Germany) tests for antibodies against the P. aeruginosa
antigens alkaline protease, elastase, and exotoxin A [8,16]
was used. Additionally, different ELISAs were used, developed
at the Medical College of Wisconsin (MCW) (Milwaukee,
Wisconsin, USA), to include the pooled P. aeruginosa antigensPopB and ExoS, PAO1 cell lysate preparation [17], and
exotoxin A to compare and calibrate to the E-15 ELISA. The
technical personnel who carried out the ELISAs were
blinded to CF subject data in the EPIC trial. Positive and
negative antibody titers were evaluated according to in-
structions of the manufacturer with regard to the E-15
ELISA, while sero-positivity using the MCW ELISA was
defined by antibody titers exceeding a cut-off value of 100.
This threshold was selected for all antigens based on earlier
results and Receiver Operating Curve (ROC) analysis of
pilot data [20].2.2. Statistical analysis
Individual antigen titers were summarized and plotted by
concurrent culture status. Concordance, defined as the propor-
tion of samples that were both sero-positive and culture positive
or sero-negative and culture negative, and diagnostic proper-
ties, including sensitivity, specificity, positive predictive value,
and negative predictive value, were calculated for the E-15 and
MCW combined ELISAs (if any one antigen in the ELISA is
positive, the combined ELISA is positive) and for each antigen
individually. P. aeruginosa positivity was plotted over time for
the E-15 and MCW ELISAs in addition to culture. Modified
Leeds criteria were used to group subjects according to
P. aeruginosa culture positivity over the course of the 70 week
study [21]: P. aeruginosa free, intermittentP. aeruginosa (at least
one positive but less than half of the subject's cultures) or chronic
P. aeruginosa (50% or more of a subject's cultures are P.
aeruginosa positive). Antigen titers were plotted as a function of
these categories. Odds ratio and 95% confidence intervals were
calculated to evaluate the relationship between sero-positivity at
baseline, week 0, and at eradication of the pathogen at week 10
(unable to isolate with OP swab culture). In subjects who were
culture negative at week 10, time to next P. aeruginosa isolation,
determined by culture, was analyzed as a function of sero-
positivity at baseline using time-to-event analyses and the
log-rank test. Likewise, time to pulmonary exacerbation was
analyzed as a function of baseline sero-positivity. Analyses were
performed using R 2.11.1 (R Foundation for Statistical Computing,
Vienna, Austria).3. Results
There were 304 CF subjects in the EPIC trial [19]. From 303
subjects, serum and culture data were available for P. aeruginosa
serology analysis, resulting in 975 paired serum/culture speci-
mens over the four time points at weeks 0, 22, 46 and 70 (see
Supplement Fig. 1). Among those with baseline serum, 238
(92.9%) had week 10 presence or absence of P. aeruginosa by
culture to determine the success of antibiotic treatment in
eradicating the pathogen (unable to isolate with OP swab
culture). Baseline characteristics of the entire subject cohort and
the week 10 P. aeruginosa culture status have been reported
elsewhere [19,22].
Fig. 1. Distribution of individual antigen titers by concurrent culture status for all 975 serum samples. Pa+ indicates P. aeruginosa positive, Pa− indicates P. aeruginosa
negative. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range), whiskers extend to minimum and maximum or 1.5× the
inter-quartile range (whichever is smaller), outliers are marked as circles.
Fig. 2. Culture positivity and seropositivity over time. The solid black line
shows the proportion culture positive for P. aeruginosa across each visit among
the 303 subjects with available serology. The dashed lines show the proportion
of samples seropositive at each visit for each combined ELISA. A combined
ELISA is defined as seropositive if any one of the three antigens in an ELISA
has titer at least 100.
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To investigate whether serological results from the individ-
ual antigens used in the ELISAs would correlate with the
P. aeruginosa culture status of the CF subject, ELISA results
for each antigen were pooled over all time points and compared
with the P. aeruginosa culture status. In an attempt to
maximize the detection of serum antibodies directed against
P. aeruginosa, we used in our analysis a broad panel of
P. aeruginosa antigens, including the extracellular toxins
alkaline protease, elastase, exotoxin A and exotoxin S, the pore
protein PopB and a PAO1 cell lysate preparation. Sera from CF
subjects who were P. aeruginosa culture-positive revealed
higher antibody titers than sera from P. aeruginosa culture-
negative CF subjects (Fig. 1). The spread of titer values was
highest in E-15 ELISA alkaline protease, elastase, and
exotoxin A, while the distribution of titer values in the MCW
antigens was narrower.
To assess whether eradication of P. aeruginosa from OP
swabs during the EPIC trial period, would be reflected by a
similar loss of sero-positivity, results of the E-15 and MCW
ELISAs were plotted over the investigation period and compared
with data from P. aeruginosa cultures. While P. aeruginosa
culture positivity sharply declined from 40% at baseline to
approximately 12% at subsequent visits in accordance with
antibiotic treatment, antibody titers against P. aeruginosa
antigens used in the E-15 and MCW ELISAs declined only
slightly from 63% and 47% at baseline to 52% and 38% at week
70, respectively (Fig. 2).
Next we assessed whether the ELISAs might be used
to differentiate between P. aeruginosa free, intermittentP. aeruginosa, and chronic P. aeruginosa, as defined by the
modified Leeds criteria [21]. Participants who were chronical-
ly P. aeruginosa culture positive had generally higher baseline
serology than those who were only intermittently culture
positive and those who never turned P. aeruginosa culture
positive by the end of the study (Fig. 3). Persistence of high
titers over the course of the study was observed in individuals
with chronic P. aeruginosa infection (Supplement Fig. 2), and
at week 70, titers from chronically P. aeruginosa culture
positive subjects were significantly higher than those who
Fig. 3. Baseline serology titers by respiratory culture status using modified Leeds criteria. Subjects were classified as ‘Pa free’ if they were clear of P. aeruginosa
from baseline through end of study, ‘Intermittent’ if they had less than half of all available cultures testing positive for P. aeruginosa, and ‘Chronic’ if they had half or
more of all available cultures testing positive for P. aeruginosa. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range),
whiskers extend to minimum and maximum or 1.5× the inter-quartile range (whichever is smaller), outliers are marked as circles.
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antigens (p-valuesb0.01).
Pooled concordance across the four time points ranged from
0.60 to 0.79 between the individual antigens and respiratoryTable 1
Frequency and diagnostic properties of individual and combined ELISAs.
P.aeruginosa Culture Sensitivity
Antigen − +
Alkaline protease d − 633 109 0.45
+ 144 89
Elastase d − 608 95 0.52
+ 169 103
Exotoxin A d − 449 65 0.67
+ 328 133
PopB+ExoS e − 647 102 0.48
+ 130 96
PAO1 cell lysate e − 560 79 0.60
+ 217 119
Exotoxin A a − 716 146 0.26
+ 61 52
E-15 combined d − 371 44 0.78
+ 406 154
MCW combined e − 502 61 0.69
+ 275 137
a PPV refers to positive predictive value.
b NPV refers to negative predictive value.
c Concordance is the proportion of all 975 samples that were culture negative/ser
d Component of Mediagnost® E-15 ELISA kit (Reutlingen, Germany).
e Studies conducted at Dr. Joseph Barbieri's laboratory, Medical College of WiscP. aeruginosa culture results (Table 1). Among the discordant
pairs, serum antibody titers were more often positive than
P. aeruginosa cultures with regard to the E-15 antigens
alkaline protease (144/253), elastase (169/264), exotoxin ASpecificity PPV a NPV b Concordance c
0.81 0.38 0.85 0.74
0.78 0.38 0.86 0.73
0.58 0.29 0.87 0.60
0.83 0.42 0.86 0.76
0.72 0.35 0.88 0.70
0.92 0.46 0.83 0.79
0.48 0.28 0.89 0.54
0.65 0.33 0.89 0.66
onegative or culture positive/seropositive.
onsin.
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and PAO1 cell lysate (217/296). Assuming the respiratory
P. aeruginosa culture as standard of care, the sensitivities
for the individual antigens were low, ranging from 0.26 to
0.67. In comparison, specificity of the individual antigens was
relatively high, ranging from 0.58 to 0.99, indicating that a
large fraction of samples had titers less than the reciprocal
cut-off titer of 100 among culture negative events. The positive
predictive values for the single ELISA antigens were low
(b0.5), whereas the negative predictive values were moder-
ately high (0.83–0.88). Combining antigens, as exemplified in
the E-15 ELISA improved the sensitivity (E-15: 0.78; MCW:
0.69) while decreasing the specificity (E-15: 0.48; MCW:
0.69).
3.2. Predictive utility of P. aeruginosa serology
Next we sought to know whether a positive antibody titer
against one or several of the P. aeruginosa antigens at baseline
in CF subjects was associated with eradication or time to
next positive P. aeruginosa culture after successful eradication.
Eradication rate of P. aeruginosa at week 10 among those with
baseline serology was 207/238 (86.9%). Boxplots of baseline
antibody titers for each of the antigens by eradication status at
week 10 (Supplement Fig. 3) indicated that there were some
slightly increased baseline titers in those who failed to eradicate at
week 10, but there was an overlap in the serology values between
the two groups and thus not statistically significant. Baseline
serology (seropositive or seronegative) in the combined E-15
ELISA was not found to have a significant relationship with
initial eradication success after adjusting for baseline culture
status (OR=1.97, 95% CI=[0.75, 5.19], p-value=0.17). Simi-
larly, the combined MCW ELISA for baseline serology was not
significantly associated with initial eradication after adjusting for
baseline culture status (OR=1.2, 95% CI=[0.53 , 2.73],
p-value=0.66).
Using a Cox Proportional Hazard model, we demonstrate
that positive baseline antibody titers against the E-15 ELISA
antigens alkaline protease and exotoxin A were both signifi-
cantly associated with a higher risk of P. aeruginosa re-
isolation in the 60 weeks after eradication (HR=2.20, 95%
CI= [1.30, 3.71], p-value =0.003) and (HR=2.50, 95% CI=Table 2
Hazard ratios for risk of P. aeruginosa occurrence post eradication treatment.
Antigen Hazard ratio Hazard ratio 95% CI p-value
E-15 Alkaline protease 2.19 (1.30, 3.71) 0.003
Elastase 1.66 (0.99, 2.78) 0.055
Exotoxin A 2.50 (1.42, 4.39) 0.001
Combined 1.68 (0.96, 2.95) 0.072
MCW PopB+ExoS 1.51 (0.89, 2.56) 0.120
PAO1 cell lysate 1.61 (0.97, 2.68) 0.068
MCW exotoxin A 1.69 (0.89, 3.18) 0.106
Combined 1.38 (0.83, 2.31) 0.219
Post-eradication is week 10 onward. Each hazard ratio is attributable to baseline
seropositivity against the individual antigens, combined E-15 ELISA, and
MCW ELISA. A combined ELISA is defined as seropositive if any one of the
three antibodies in an ELISA has titer at least 100.[1.42.4.40], p-value=0.001), respectively (Table 2). Sero-
positivity at baseline for all other ELISA antigens and the
combined ELISAs were found to increase the risk of
P. aeruginosa recurrence but this finding was not statistically
significant.
A similar question was whether a positive antibody titer
against one or several of the P. aeruginosa antigens at baseline
in CF subjects in whom P. aeruginosa was successfully
eradicated would be associated with a shorter time to next acute
pulmonary exacerbation; the primary clinical outcome of the
EPIC trial. Results based on the E-15 ELISA revealed that
sero-positive CF subjects did not have a different risk for
pulmonary exacerbation requiring antibiotics or hospitalization
than those who were sero-negative at baseline (CI=1.1, 95%
CI= [0.77, 1.57], p-value=0.61).
4. Discussion
Our study of serology in the EPIC trial examines the utility
of blood antigen detection as a prognostic marker of subsequent
OP culture isolation after initial eradication of Pa from upper
respiratory tract swabs. In addition, the use of serology as a
prognostic marker of key clinical outcomes such as pulmonary
exacerbations was evaluated. We report that elevation of 2
antigens, exo A and alkaline protease, prior to eradication
therapy in CF subjects in whom P. aeruginosa was successfully
eradicated, was significantly associated with a higher risk of
P. aeruginosa re-isolation during the 60 week follow-up
period. Serology was not predictive, however, of pulmonary
exacerbation during this time period. As displayed in Fig. 2, it
is evident that OP swabs and Pa serology have different time
courses in response to early Pa infection. Antibody response
against P. aeruginosa was high initially, and serum antibody
titers remained elevated over the course of the study period,
while P. aeruginosa culture positivity dropped significantly at
the end of the first treatment course It is therefore not surprising
that only a moderate rate of concordance was observed between
serology and culture collected at the same time,. It is well
established [7,9] that OP culture is by no means a perfect
diagnostic indicator for lower or upper airway P. aeruginosa
infection; however in the US it is the standard of care [6]. The
very fact that serology does not exactly mimic culture results,
highlights the complementary potential of P. aeruginosa
serology in CF.
The diagnostic and concordance results alone make it
impossible to determine if serology characterizes residual Pa
infection, precursor to infection, or if the discordance is a
product of the limitations of OP. Host response to initial
P. aeruginosa infection appears to be variable in cystic fibrosis.
Our results confer that early P. aeruginosa infection does not
always elicit a serologic response [9], and conversely, serology
often perpetuates when respiratory culture is Pa negative— the
latter being more often the case. The sustained elevation of
serology when OP culture positivity appears to wane may be
due to slow disappearance of P. aeruginosa-positive plasma
cells after the eradication of the antigenic stimulus in the
organism or due to persistence of P. aeruginosa antigens in
152 M. Anstead et al. / Journal of Cystic Fibrosis 12 (2013) 147–153obstructed airways of CF subjects despite negative P. aeruginosa
culture results.
In previous studies [2,8,13] a P. aeruginosa ELISA had
been used to monitor the success of the antibiotic intervention
in CF subjects for eradication of early P. aeruginosa infection
based upon the return of elevated serum antibodies toward
normal levels. We could not confirm these findings in the
present study as there was no statistically significant association
between baseline serology and eradication rate at week 10 after
adjusting for baseline culture status. We note above, however,
that positive antibody titers against 2 antigens, alkaline
protease and exotoxin A, were significantly associated with a
higher risk of P. aeruginosa re-isolation. These data suggest
that previous P. aeruginosa isolation may predispose a CF
patient to a subsequent P. aeruginosa isolation episode in a
shorter time period. Thus, CF patients with new acquisition of
P. aeruginosa and positive serology may benefit from closer
monitoring (by culture or culture-independent techniques
[23–25]) than those with negative serology, enhancing the
ability to quickly treat recurrent infection. Because serology
appears to contain information not captured by OP culture,
or BAL [9] culture, we hypothesize that a combination of
detection methods may yield better diagnosis and prognosis
than does each independently [23–25]. The design of the EPIC
study did not provide the ideal setting to answer questions
about optimal surveillance algorithms using OP and serology in
combination. Rather, the results compel the CF community to
consider evaluation of potential protocols through prospective
trials — which may include serology, OP, BAL, sputum, or
polymerase chain reaction genomic identification methods.
Two and three stage screening programs, where no one
diagnostic tool is sufficient, can provide effective monitoring
[26,27]. The combination of screening tools in other disease
settings such as cervical [28,29] and prostate [30,31] cancer
yields accurate disease detection. Only prospective trials
comparing different surveillance algorithms will confirm
efficacy and effectiveness on an individual level.
Since all subjects in the EPIC clinical trial had a new or
recent P. aeruginosa positive respiratory culture and the time
period of the trial was relatively short, a longitudinal analysis of
the correlation between the time period of P. aeruginosa culture
positivity and serological data in CF subjects was not possible.
Serologic data from the observational cohort of the EPIC study
are currently being analyzed and will provide further insights
into the longitudinal relationship between P. aeruginosa serology
and P. aeruginosa culture results.
From a pathophysiological standpoint, it is still unclear, how
the findings in the sero-positive CF cohort with higher risk for
earlier P. aeruginosa isolation could be interpreted. Possibly,
this group may have previously had a higher number of
P. aeruginosa isolations, a higher bacterial burden in the airways,
and as a consequence, more lung tissue damage than those CF
patients with sero-negative baseline findings. The notion that
specific antibodies against P. aeruginosa antigens augment lung
inflammation and tissue damage due to immune complex
mediated type III reactions, resulting in worse long term
prognosis, has been repeatedly demonstrated in the past [32–35].Ultimately patient experience and clinical endpoints deter-
mine the usefulness of any diagnostic tool or monitoring
algorithm. There was no statistically significant association
between baseline serology with pulmonary exacerbation requir-
ing antibiotics or hospitalization over 60 weeks of follow-up;
however our findings and those from other investigators would
suggest that P. aeruginosa serology may have diagnostic and
prognostic value to CF clinicians in their efforts to early detect
re-isolation of P. aeruginosa. Prospective, randomized trials of
monitoring algorithms inclusive of serology, and culture, and
culture independent methods are needed to evaluate effectiveness
of P. aeruginosa monitoring protocols on clinical outcomes in
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